NEUNEUREN PHARMACEUTICALS LIMITED
Announcement history available from 1 August 2025
Fromto
| Date / Time | Title | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 5 Aug 2026, 19:52 | Record Q2 DAYBUE net sales of US$125m, CY26 royalty upgraded | Company Update | MS | 11001 | |
| 24 July 2026, 19:57 | Neuren highlights participation in PMSF Family Conference | Company Administration | — | 12008 | |
| 29 June 2026, 17:43 | DAYBU recommended for approval in the European Union | Company Update | MS | 11001 | |
| 19 June 2026, 02:49 | Application for quotation of securities - NEU | Other | — | 06020 | |
| 2 June 2026, 03:47 | Notification of cessation of securities - NEU | Other | — | 06027 | |
| 2 June 2026, 03:40 | Notification regarding unquoted securities - NEU | Other | — | 06021 | |
| 28 May 2026, 02:00 | Results of Meeting | Meetings & Governance | — | 08003 | |
| 27 May 2026, 23:22 | AGM Chair Address & CEO Presentation | Presentations | MS | 03026, 15002 | |
| 14 May 2026, 17:30 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 13 May 2026, 01:56 | Launch of Investor Hub to enhance shareholder engagement | Company Administration | — | 12008 | |
| 12 May 2026, 18:34 | Notification of cessation of securities - NEU | Other | — | 06027 | |
| 12 May 2026, 18:32 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 11 May 2026, 18:45 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 7 May 2026, 19:53 | Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025 | Company Update | MS | 11001 | |
| 6 May 2026, 20:31 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 29 Apr 2026, 18:45 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 24 Apr 2026, 23:27 | Virtual AGM online guide | Meetings & Governance | — | 08001 | |
| 24 Apr 2026, 23:22 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 | |
| 24 Apr 2026, 23:05 | Appendix 4G | Company Administration | — | 03025 | |
| 24 Apr 2026, 22:58 | 2025 Annual Report to shareholders | Financial Results | — | 03001, 03002, 03011, 03012 | |
| 21 Apr 2026, 18:56 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 20 Apr 2026, 18:32 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 17 Apr 2026, 18:48 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 11 Apr 2026, 02:55 | Notification of cessation of securities - NEU | Other | — | 06027 | |
| 8 Apr 2026, 19:47 | DAYBUE STIX now broadly available in US for Rett syndrome | Company Update | MS | 11001 | |
| 27 Mar 2026, 04:49 | Notification of cessation of securities - NEU | Other | — | 06027 | |
| 24 Mar 2026, 19:40 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 13 Mar 2026, 19:26 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 10 Mar 2026, 19:40 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 6 Mar 2026, 21:25 | Change of Director's Interest Notice - J Basile | Director Interests | — | 02009 | |
| 4 Mar 2026, 19:42 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06012 | |
| 3 Mar 2026, 20:50 | Acadia confirms plan to request CHMP re-examination | Company Update | MS | 11001 | |
| 27 Feb 2026, 22:54 | Investor presentation, 27 February 2026 | Presentations | — | 03026 | |
| 27 Feb 2026, 20:59 | 2025 royalty income A$65m, profit after tax A$30m | Financial Results | MS | 03003, 03014 | |
| 27 Feb 2026, 20:53 | Appendix 4E and 2025 full year accounts | Financial Results | MS | 03003 | |
| 26 Feb 2026, 22:15 | Acadia reports DAYBUE net sales for 2025 and 2026 guidance | Company Update | MS | 03014, 11001, 12008 | |
| 26 Feb 2026, 20:53 | Pause in Trading | Trading Halt / Suspension | MS | 09005 | |
| 13 Feb 2026, 20:32 | Update - Notification of buy-back - NEU | Buybacks & Capital Management | — | 06011 | |
| 12 Feb 2026, 05:24 | Notification of buy-back - NEU | Buybacks & Capital Management | — | 06011 | |
| 12 Feb 2026, 04:05 | Notification of Neuren investor webinar on 12 February 2026 | Presentations | — | 14014 | |
| 12 Feb 2026, 04:00 | Neuren to commence new on-market share buy-back program | Buybacks & Capital Management | MS | 06011 | |
| 6 Feb 2026, 20:26 | First patient dosed in Neuren PMS Phase 3 trial | Company Update | MS | 11001 | |
| 5 Feb 2026, 19:11 | Priority Review Voucher program reauthorized by US Congress | Company Administration | — | 12008 | |
| 5 Feb 2026, 04:07 | Neuren receives US FDA meeting feeback for HIE and PTHS | Company Update | MS | 09014, 11001 | |
| 4 Feb 2026, 21:14 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 4 Feb 2026, 20:57 | Pause in Trading | Trading Halt / Suspension | MS | 09005 | |
| 3 Feb 2026, 20:40 | Acadia provides update on EU regulatory submission | Company Update | MS | 11001 | |
| 19 Jan 2026, 20:10 | Response to ASX Aware Letter | ASX Query | MS | 17003 | |
| 14 Jan 2026, 21:26 | DAYBUE net sales projected to reach approx US$700m in 2028 | Company Update | MS | 11001 | |
| 7 Jan 2026, 21:20 | NNZ-2591 PMS Phase 2 trial published in Neurology Genetics | Company Update | — | 11001 |
1–50 of 68
1 / 2